Australia expands subsidized medicine access for cancer and thyroid disease patients

The Australian government has expanded the Pharmaceutical Benefits Scheme to include new treatments for cystic fibrosis, blood cancer, and thyroid eye disease.

The Australian government has expanded access to subsidized medicines for patients with cystic fibrosis, blood cancer, and thyroid eye disease under the Pharmaceutical Benefits Scheme (PBS), Health Minister Mark Butler said on Sunday.

Effective Nov. 1, children aged six to 11 with cystic fibrosis who weigh less than 30 kg will be eligible for a granule form of Trikafta. This formulation is designed to help children who have difficulty swallowing tablets. About 3,300 Australians are expected to benefit from the expanded listing each year.

The government has also added Tepezza to the PBS as a treatment for active, moderate-to-severe thyroid eye disease, which is expected to benefit around 310 Australians annually. Additionally, subsidized access to Adcetris has been expanded to provide a new first-line treatment option for patients with advanced CD30-positive classical Hodgkin lymphoma. This change is estimated to benefit 370 Australians each year.

The PBS listing for Repatha, a medicine used to treat high cholesterol, has been amended to allow eligible patients to obtain larger quantities under the government's 60-day prescription initiative.

Under the PBS, eligible patients will pay a maximum of 25 Australian dollars per prescription, or 7.70 Australian dollars for concession card holders. Without PBS subsidies, the Trikafta treatment could cost patients more than 20,300 Australian dollars per prescription.

The government said it has approved additional funding for 511 new and amended PBS listings since July 2022.

Key facts

  • Trikafta granules will be available for children aged six to 11 with cystic fibrosis weighing less than 30 kg starting Nov. 1.
  • Tepezza has been added to the PBS for active, moderate-to-severe thyroid eye disease.
  • Adcetris is now a subsidized first-line treatment option for advanced CD30-positive classical Hodgkin lymphoma.

Three perspectives

Neutral

The Australian government has expanded the Pharmaceutical Benefits Scheme to include several new medicine listings and formulations.

Positive

The expansion provides subsidized access to essential treatments for thousands of Australians, including a granule form of Trikafta for children who have difficulty swallowing tablets.

Negative

Without PBS subsidies, the Trikafta treatment could cost patients more than 20,300 Australian dollars per prescription.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Next storyHealth department aims to eliminate cervical cancer by 2030

All sections

Edition